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We have previously established that the tissue-specific activity of the hepatitis B virus (HBV) enhancer is
mediated by trans-acting cellular factors. Here we have studied in vitro the interactions between the HBV
enhancer DNA and cellular factors present in nuclear extracts from both liver and nonliver cell types. The
results presented in this study imply the involvement of several distinct, ubiquitous, and liver-specific cellular
factors with the HBV enhancer. Sequence analysis of the binding sites for these proteins on HBV DNA showed
homologies to sequence motifs known to bind other previously characterized and purified transcription factors
including CAAT/enhancer-binding protein. Thus, all of these binding sites may function in concert to activate
liver-specific transcription of HBV genes from their respective promoters.
Human hepatitis B virus (HBV), a member of the Hepad-
naviridae family, is a small DNA virus that exhibits marked
liver tropism (for reviews, see references 11 and 29). Such
hepatotropic expression may be due to preferential attach-
ment and entry into hepatocytes, liver-specific viral regula-
tory elements, or both. One such HBV regulatory element
that has generated interest is the viral enhancer (37, 40).
Transcriptional enhancers, including the HBV element, are
cis-acting regions of DNA that can potentiate transcription
from autologous and heterologous promoters in a relatively
position- and orientation-independent manner (16, 37, 40).
The HBV enhancer element is strategically placed (Fig. 1A)
3' to the surface antigen gene and 5' to the core and X
antigen genes and is included in the coding frame of the
putative polymerase gene. Such a location makes it plausible
for the enhancer to modulate activity of the core and X
promoters located downstream and the surface antigen pro-
moter(s) located upstream. Requirement of the enhancer for
efficient expression of S antigen and X genes has been
previously demonstrated (2, 16, 38). Furthermore, it is the
only enhancer, to our knowledge, whose sequences are part
of mature transcripts, in this case the 2.1-kilobase surface
antigen mRNA and the 3.5-kilobase RNA species including
the pregenomic RNA (for a review, see reference 11).
It has been previously shown by means of gene transfer
experiments that the HBV enhancer exhibits cell type spec-
ificity for human hepatoma cells and that this specificity is
due to trans-acting factors (16, 37). There is substantial
evidence for the involvement of a variety of proteins in the
regulation of transcription (12, 20, 28, 32, 39). The binding
sites for such trans-acting protein factors have been mapped
on a number of viral and cellular enhancers (3, 29, 32-35,
41). It is now becoming increasingly evident that the en-
hancer-mediated transcriptional activation and tissue speci-
ficity involve interactions between conserved sequence mo-
tifs on the DNA and closely related cellular factors. The
mechanisms for such a regulatory control, however, have
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yet to be established. A cassette-shuffling model has been
proposed to explain the substantial overlap seen between
various enhancers in terms of sequence motifs and the
factors that bind to them (34).
Because of the host and tissue specificities of the HBV
enhancer, we set out to identify and characterize in detail the
nature of the protein-DNA interactions between trans-acting
cellular factors and the HBV enhancer element. Using
DNase I protection analysis, we define here the binding sites
of both liver-specific and ubiquitous factors on the enhancer
element and discuss their possible significance in HBV gene
expression.
MATERIALS AND METHODS
Cell lines and extracts. Huh-7 (25) and HepG2, human
hepatoma cell lines that are negative for HBV sequences,
and HeLa, a human cervical carcinoma cell line, were used.
Nuclear extracts were prepared from HeLa, Huh-7, rat liver,
and spleen tissues. Cultured cell lines were grown in Dul-
becco modified Eagle medium supplemented with 10% fetal
bovine serum and antibiotics (75 U of penicillin and 50 mg of
streptomycin per ml). Nuclear extracts from HeLa and
Huh-7 cells were prepared by the method of Dignam et al.
(7). Extraction of nuclear proteins from rat liver and spleen
was carried out by the method of Johnson et al. (18). Protein
concentrations were determined by using the Bio-Rad pro-
tein assay kit and were typically between 3 and 12 mg/ml.
Extracts were stored at -70°C. Luciferase assays were
carried out by the method of de Wet et al. (6). Cell transfec-
tions were by the CaPO4 method (14). Plasmid pSV2CAT
(13) was used as a control plasmid to normalize the trans-
fection values for the differential uptake by different cell
lines. Methods of isolation, propagation, and immortaliza-
tion of rat primary hepatocytes to generate cell line CWSV1
have been previously described (42).
Plasmids and preparation of labeled probes. The 342-base-
pair HpaI-HpaII (from nucleotide [nt] 966 to 1308) fragment
of HBV DNA (Fig. 1) was isolated and subcloned into
plasmid pSP65 at its HindII site to produce the plasmid
pEnh. Radiolabeled probes were prepared by digesting pEnh
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FIG. 1. (A) HBV genome with open reading frames (S, C, X, and P) and promoters (P1, P2, Xp, and Cp). (B) Enhancer region showing
the distribution of various protein-binding regions. Expression of firefly luciferase gene under the transcriptional control of either the HBV
core gene promoter, pABluc (AvaI-BglII, nt 1466 to 1987), or the SV40 early promoter region (41) and the HBV enhancer fragments A
(pEnS41uc), B (pEnS11), and C (pEnS41) located upstream. The levels of luciferase expression are presented as fold stimulation expressed
as light units above the background levels obtained with either the HBV core gene or the SV40 early promoter alone without the HBV
enhancer. HepG2 and Huh-7 cells were derived from human hepatomas, and CWSV1 cells were derived from primary rat hepatocytes (42).
ND, Not done.
at either the BamHI or HindIlI site of the SP65 polylinker,
dephosphorylating the 5' end with calf intestine alkaline
phosphatase, and end labeling the 5' ends with [-y-32P]ATP
(>4,000 Ci/mM; ICN Pharmaceuticals, Inc.) by T4 polynu-
cleotide kinase (United States Biochemicals). The DNA was
then digested with another restriction enzyme to produce
fragments labeled at one terminus. Smaller labeled frag-
ments were prepared by cutting at the AccI site (nt 1074)
within the HBV enhancer followed by 5'-end labeling. The
probes were purified and eluted from 6% native polyacryl-
amide gels. The specific activities typically ranged between 3
x 104 and 1 x 105 cpm/ng of DNA.
DNase I protection analysis. For DNase I protection anal-
ysis (10), 5 to 10 pmol of probe (about 50,000 cpm) was
mixed with 1 ,ug of poly(dI dC) and an appropriate amount
of nuclear extract (0 to 150 Rg) in a final volume of 50 ,ul of
binding buffer (20 mM HEPES [N-2-hydroxyethylpipera-
zine-N'-2-ethanesulfonic acid] [pH 7.9], 20% glycerol, 0.1 M
KCI, 0.2 mM EDTA, 2 mM dithiothreitol). After binding on
ice for 15 min, 50 RI of a solution containing 5 mM CaCl2 and
10 mM MgCl2 was added to each tube. After a 1-min
incubation at room temperature, an appropriate amount
(empirically determined) of freshly diluted DNase I was
added and the digestion was carried out for exactly 1 min at
room temperature. The digestion was quenched with 90 RI of
stop buffer (0.2 M NaCl, 0.03 M EDTA, 1% sodium dodecyl
sulfate, 100 ,ug of tRNA per ml). The samples were extracted
once with phenol-chloroform, and the aqueous phase was
precipitated with ethanol. The pellets were dried and sus-
pended in 8 of loading buffer (0.1 M NaOH-formamide
[1:2, vol/vol], 0.1% xylene cyanol, 0.1% bromophenol blue).
After heating for 5 min at 100°C, 4 pI of each sample was
subjected to electrophoresis, as described earlier. Marker
sequencing ladders were generated by using homologous
fragments by the method of Maxam and Gilbert (23).
For footprint competition, a 50- to 100-fold molar excess
of either homologous or heterologous fragments or oligonu-
cleotides was mixed with the corresponding HBV enhancer
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FIG. 2. DNase I protection analysis of fragment B (AccI-HpaII, nt 1074 to 1308) of HBV enhancer by factors contained in the nuclear
extracts from HeLa cells (A), Huh-7 cells (B), and RLNE (C). Fragments were 5' end labeled at the AccI site (coding strand). l, Region of
DNase I protection; 4, hypersensitive site. The amounts of nuclear proteins used are given in micrograms (0 to 100 ptg).
probe fragments and incubated with rat liver nuclear extract
(RLNE).
RESULTS
The HBV enhancer has been previously mapped on the
genome from nt 966 to 1308 (37, 40). To compare the
activities of the HBV enhancer among the various liver and
nonliver cells, we used the firefly luciferase reporter gene in
a transient scheme of expression (6). The luciferase gene
(luc) expression plasmids (Fig. 1B) and enhancer sequences
contained either the simian virus 40 (SV40) early promoter
(41) (pEnS41uc) or the HBV core gene promoter (pABluc).
The relative levels of induction of luc gene activity in the
liver-derived cell lines (Huh-7, HepG2, and rat hepatocytes)
and nonliver HeLa cells are shown in Fig. 1B. The levels of
induction of luciferase activity with fragment A ranged from
30- to 70-fold above the values obtained with either the
luciferase expression plasmid pSV232luc (with the enhancer-
less SV40 early promoter) (6) or pABluc (the HBV core and
pregenomic promoter) in liver-derived cell lines but were
only fivefold greater in HeLa, establishing its cell type-
specific enhancer activity. The luc activity with fragment B
showed approximately similar levels of stimulation, whereas
fragment C was insufficient for full enhancer activity (Fig,
1B). These data are in agreement with data from previous
studies from this and other laboratories (1, 16, 37). All
transfection experiments include an independent plasmid
containing an SV40-driven chloramphenicol acetyltransfer-
ase (13) gene that was used to monitor transfection efficiency
(data not presented). Of interest in the present study is the
demonstration of enhancer function in CWSV1, a cell line
derived from rat hepatocytes that have been immortalized by
SV40 T antigen (42). In contrast to our previous results, in
which HBV enhancer function was shown to be restricted to
human liver cell lines, these results clearly show that a cell
line derived from rat hepatocytes can support enhancer
activity. Further support for this observation is provided by
the recent success of replication and expression of the HBV
genome in transgenic mice (8).
Multiple factors bind to the HBV enhancer. Because of the
observed liver cell type specificity, DNase I protection
analysis (10) was carried out to define the binding sites of
cellular factors with the enhancer element. For DNase I
VOL. 63, 1989
5296 PATEL ET AL.
A CB
HeLa
tJ RC I f
RLNE
0 3 10 30 0
.
HIu h-7
.: 10 50 ir cs
'm w 4
b -
4 ,
LI
o .
VIll
ViI
VI
I
J 't-'' S_...... . - .. ....
,si GTF
.:
_3,*i Zw ... - F
... 3l," ... ..
s ^
.
,^e F *
:.:.t tPS ...... >. . ....
.1Rir "'
iw
w 1t
X E
w. l
5;[
sv :wtF *
.^
*-t.
.4j **g1!r eleZ
**See R*.*..**.
s-p
X-si w
vi
FIG. 3. DNase I protection analysis of fragment C (HpaI-AccI, nt 966 to 1074). Nuclear extracts used were from HeLa cells (A), Huh-7
cells (B), and RLNE (C). Symbols are as defined in the legend to Fig. 2.
protection analysis, the 342-base-pair HpaI-HpaII (nt 966 to
1308) fragment A (Fig. 1) was subdivided into fragments B
(AccI-HpaII, nt 1074 to 1308) and C (HpaI-AccI, nt 966 to
1074) by using the convenient restriction site AccI (nt 1074).
All three fragments (A through C) were subsequently used as
probes. All DNase I protection experiments were carried out
in the presence of excess poly(dI dC). The digests were
then fractionated with homologous nucleotide sequence lad-
ders on denaturing polyacrylamide gels. Treatment of the
extracts with proteinase K or heat at 99°C for 15 min prior to
DNase I digestion abolished all footprints (data not shown).
The footprint analysis of fragment B (AccI-HpaII, nt 1074 to
1308) incubated with nuclear extracts prepared from HeLa,
Huh-7, and RLNE is shown in Fig. 2. At least four distinct
footprints, designated FP-I to FP-IV, were observed within
the HBV enhancer fragment B on the coding (Fig. 2) as well
as on the noncoding (data not shown) strand with all the
extracts used. An additional footprint, FP-V, was also
observed only in the presence of RLNE extract (Fig. 2C).
This footprint, however, was weak with Huh-7 extracts.
Thus it is difficult at this time to suggest that this interaction
is liver specific. The nucleotide sequence of each of these
protected regions and its relative position on the HBV
enhancer element are summarized in Fig. 6. The five foot-
print regions map between nucleotide sequence positions:
1208 and 1238 (FP-I), 1168 and 1204 (FP-II), 1150 and 1164
(FP-III), 1087 and 1116 (FP-IV), and 1120 and 1137 (FP-V).
Most of the protected regions are flanked by hypersensitive
sites. Similar, if not identical, DNase I footprint patterns
were obtained for FP-I to FP-V with nuclear extracts from
both liver- and non-liver-derived cells or tissues (Fig. 2, and
see Fig. 4), indicating the ubiquitous nature of the factors
binding to the various sequence motifs contained in this
fragment.
DNase I protection analysis of fragment C (HpaI-AccI, nt
966 to 1074) revealed at least three principal areas of
interaction with liver extracts (FP-VI through FP-VIII). The
FP-VIII interaction is not immediately evident with Huh-7
extracts. When HeLa cells were used, we did not observe
any noticeable binding in this fragment (Fig. 3A). FP-VI is
protected between nucleotide positions 1017 and 1045, FP-
VII is protected between nt 993 and 1009, and FP-VIII is
protected between nt 971 and 991. Each region of protection
was again flanked by hypersensitive sites. Interestingly, with
the Huh-7 extract (Fig. 3B), the protected region of FP-VI
contained several internal hypersensitive sites compared
with the FP-VI ofRLNE (Fig. 3C), indicating the binding of
at least two or more factors to this region. Alternatively,
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FIG. 4. DNase I protection analysis of the entire HBV enhancer
fragment A (Hpal to HpaII, nt 966 to 1308) by factors contained in
RLNE or spleen nuclear extracts. Lane 0 (middle) was overdigested
with DNase I in the upper portion of the autoradiogram. Symbols
are as defined in the legend to Fig. 2.
several factors present in RLNE may also bind to this region
but with overlapping target sites. Thus, the factors binding to
the nucleotide sequences in FP-VI to FP-VIII appear to be
liver specific.
We next subjected the entire enhancer fragment A to
DNase I protection analysis. The footprinting pattern with
fragment A (the coding strand) was similar to that seen with
subfragments B and C, demonstrating that dissection of the
enhancer fragment did not have any noticeable effect on the
overall footprinting pattern (Fig. 4). Footprints FP-VI to
FP-VIII were not observed in the presence of spleen nuclear
extracts, thereby reaffirming the liver-specific nature of the
factors. The general footprinting patterns with RLNEs are
noticeably clear compared with those of human hepatoma
cell line extracts, perhaps indicating the abundance of these
proteins in tissues compared with their abundance in cell
lines (Figs. 2 through 5).
A sequence analysis of the DNase I-protected regions
(FP-I to FP-VIII) within the enhancer element revealed
homologies to several known sequence motifs. These are
the nuclear factor (NF)-1 binding site (FP-I), the SV40
enhancer core element (FP-II and FP-VI), the polyomavirus
enhancer factor EF-C element (FP-III), and the hepatocyte
nuclear factor-i (HNF-1) sequence (FP-VI). By using some
of the sequences described above as competitors in DNase I
protection experiments, we show here that HBV enhancer
element may have the same factors as elements found in
other enhancers and promoters (Fig. 5). This is shown by
binding competitions with unlabeled oligonucleotide se-
quences and fragments corresponding to the sequence mo-
tifs. While this study attempts to demonstrate that distinct
factors may be binding to the various sequences on the HBV
enhancer element (by competitions, heat stability, and hep-
arin-Sepharose column chromatography), the identity of the
factor(s) specific to the sequence motifs remains to be
determined.
A palindrome sequence (5'-TGGCCATAGGCCA-3') in
the protected region FP-I (between nt 1223 and 1236) shows
considerable homology to the binding site for NF-1. NF-1, a
protein originally purified from HeLa cells (30), has recently
been assigned a multifunctional role, i.e., adenovirus DNA
replication and transcription (24). It has recently been shown
to be similar to the transcription factor responsible for
selective recognition of eucaryotic promoters containing the
sequence CCAAT (19). When we used a multimeric oligomer
containing the NF-1 binding site (30), we observed no
competition at the FP-I site (Fig. SA). Further, the inability
of HBV enhancer DNA to displace purified NF-1 from its
authentic binding site in a competition assay (unpublished
results of R. M. Gronostajski, Ontario, Canada, and J.
Oikarinen, University of Oulo, Finland) indicated that this
sequence, although it shows no binding to the NF-1 protein,
may be interacting with an NF-1-like family of proteins (15,
20). Ben-Levy et al. (1) recently demonstrated that NF-1
does bind to the sequences of this footprint. However, the
purification of these sequences was performed by using an
affinity column containing an NF-1-like sequence derived
from hepatitis B surface antigen promoter region, and that
may explain the different results obtained here.
DNA sequences included in FP-II and FP-VI are homol-
ogous at 7 and 6 base pairs, respectively, to the 8-base-pair
SV40 enhancer core element 5'-GTGGTTTC-3'(19). This
region of protection is effectively displaced by competition
with the SV40 enhancer-promoter fragment (Fig. 5B). A
purified liver-specific factor, C/EBP (18), has recently been
shown to bind to this sequence (22) in FP-II and FP-VI. As
mentioned earlier, FP-VI also contains the C/EBP binding
site, and juxtaposed to this sequence is the sequence with
homology to the HNF-1 sequence motif(5). The oligonucle-
otide containing the HNF-1 binding sequence removes this
footprint (Fig. SC), suggesting that HNF-1 is required for the
C/EBP binding. In fact, our recent preliminary data on point
mutations in this region also lend support to this notion
(N. U. Patel, unpublished data). Another sequence (CTGAC
GCA), which is a part of FP-II, has considerable homology
to the AP-1/jun binding site (20). Ben-Levy et al. (1) identi-
fied this sequence in the enhancer to be 12-O-tetrade-
canoylphorbol-13-acetate inducible. Immediately adjacent to
FP-II, with an internal hypersensitive site, is FP-III, which
bears perfect consensus to the polyomavirus EF-C factor-
binding sequence and has been shown to be the target site
VOL. 63, 1989
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FIG. 5. Footprint competition of fragment B (A and B) and fragment C (C) with unlabeled oligomers or fragments in the presence of
nuclear extracts from HeLa cells and RLNE. Competitors included no competitor DNA (none), the bacterial chloramphenicol acetyltrans-
ferase gene fragment used as a nonspecific control (CAT), HBV enhancer fragment AccI-HpaII (HBV), a multimeric oligomer (30) (NF-1),
and SV40 enhancer sequence PuvII-HindIII (41) (SV ori), an oligomer containing the sequence motif that binds to the protein HNF-1
5'ATTAAC-3' (5) (HNF-1), the unlabeled fragment C (HpaI-AccI) of the HBV enhancer (C), and HpaI-NcoI (nt 966 to 1375) and
HpaI-BamHI (nt 966 to 1403) HBV enhancer sequences including the X promoter. Each reaction contained a 100-fold molar excess of
unlabeled competitors. Symbols are as defined in the legend to Fig. 2.
for this factor (26). So far, sequence comparisons of foot-
print regions FP-VII and FP-VIII have not revealed any
strong homologies to any previously characterized se-
quence. Studies are under way to determine the identities of
these factors.
DISCUSSION
The tissue-specific activity of the HBV enhancer has been
well established by gene transfer methods (16, 37; Fig. 1).
We have also shown by in vivo competition experiments that
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FIG. 6. Summary of the DNase I-protected regions represented
by FP-I to FP-VIII. The boundaries of liver- and non-liver-specific
protected regions including the coding and noncoding strands are
indicated by dotted and solid boxes, respectively. Sequences show-
ing homology to previously characterized consensus motifs are
NF-1, C/EBP, EF-C, HNF-I, and AP-1/jun.
trans-acting cellular factors are important for this activity
(16, 17, 21, 22, 36). To define and begin to understand such
cellular factors, we have studied in vitro the interactions
between various cellular extracts of both liver and nonliver
cell origins and the HBV enhancer DNA. We show here by
means of DNase I protection (footprinting) analysis that the
HBV enhancer DNA contains binding sites for multiple
cellular factors, some of which appear to be ubiquitous to all
cell types while others are specific to liver cells. Interest-
ingly, in the present analysis with the crude nuclear extracts,
the target sites for these liver-specific factors all appear to be
restricted to fragment C, while the target sites for ubiquitous
factors are restricted to fragment B. However, we have
found that fragment B alone is capable of conferring both
enhancer and cell-type-specific activity, indicating that the
fragment contained all the necessary information for medi-
ating HBV enhancer activity (Fig. 1B). An 83-base-pair
sequence contained within this fragment, which will include
our FP-II and FP-III, was recently shown (1) to produce
enhancer activity, although at levels lower than those of
fragments containing all five footprints. It is entirely possible
that some footprints obtained with fragment B result from
binding of similar proteins from nonliver extracts (HeLa or
spleen tissue), but these interactions do not promote tran-
scription in nonliver cells (Fig. 1B) (16). For example,
C/EBP (22) from RLNE produces FP-II, whereas a similar
factor, EBP-1, recently isolated from HeLa cells (4), which
has been shown to bind to the SV40 enhancer core element,
may have produced FP-II from HeLa extracts.
In contrast to earlier reports, (1, 17, 21, 36), the present
study identifies several additional protein binding regions on
the functional enhancer element. These regions show strik-
ing homologies to known sequence motifs. The DNA se-
quence specificities of at least two recently purified liver
factors show homology to the sequences contained in FP-II
and FP-VI. These are C/EBP (18) and HNF-1 (5). Land-
schulz et al. (22) have shown binding of C/EBP to two
regions of the HBV enhancer, called FP-II and FP-VI in this
study. We show here that an HNF-1-specific oligomer does
compete with FP-VI (Fig. 5B). Moreover, a mutation (Patel,
unpublished results) in the HNF-1 sequences abolishes the
entire FP-VI, suggesting that a synergy between these fac-
tors and perhaps others is required to facilitate binding to the
FP-VI region. This result can be confirmed only by demon-
strating binding with HNF-1 and C/EBP proteins.
Factor(s) binding to FP-I appears to be ubiquitious. Al-
though its target sequence has close homology to the NF-1
factor, neither an NF-1 sequence oligomer (Fig. 5A) nor a
partially purified NF-1 seems to bind to FP-I. The factor(s)
binding to these region may be related to the NF-1-like
family of proteins (17, 27, 31). Factor II binds to HBV DNA
between nt 1180 and 1203. Present within this region is the
sequence 5'GTGTTTG-3', which bears close homology to
the SV40 enhancer core octamer (Fig. 6). This sequence is
found in a variety of viral and cellular enhancers (4, 20, 41)
and is shown by point mutations and deletion of the entire
sequence to be critical for enhancer activity.
The nucleotide sequences within FP-III and FP-IV are
86% homologous (10 of 12 nt match). These regions on HBV
DNA show homology to the binding site of EF-C, a factor
identified in HeLa and undifferentiated F9 embryonal carci-
noma cells, which binds to the polyomavirus C enhancer
element (26). It remains to be seen whether EF-C or a
distinct, but closely related, protein is responsible for this
binding.
The functional tissue specificity of the HBV enhancer seen
in vivo cannot be attributed to any specific interaction at this
time. Site-directed mutagenesis of the various binding sites
on the HBV enhancer implicates several factors in mediating
maximal enhancer function (Patel, unpublished results). In
the case of footprint FP-I, its importance in enhancer func-
tion was tested (i) by disruption of the FP-I sequences by
linker insertion mutagenesis of the BalI site (nt 1225) of the
enhancer fragment (Ball cleavage dissects the FP-I) and (ii)
by an expression vector in which a HpaI-BalI fragment of
the enhancer was cloned in front of the chloramphenicol
acetyltransferase gene. Both of these constructs produced
wild-type levels of enhancer function. Taken together, these
results suggest that FP-I may not be important for enhancer
activity. However, since the X promoter is juxtaposed to the
enhancer (38) and since factors binding to enhancers have
been shown to regulate or cooperate with factor(s) on
adjacent promoters (9, 20, 31), it is possible that some of the
HBV enhancer binding factors (including the factor for FP-I)
are also required for regulation of both the enhancer and
HBV promoter elements. Its functional role in X promoter
activity is presently being examined.
To date, we have identified regions within the HBV
enhancer that are target sites for factors which are both
ubiquitious and liver specific in nature. Recent evidence
suggests that the formation of cell-specific transcription
complexes requires a combinatorial synergism between both
cell-type-specific and general transcription factors bound to
the regulatory regions (20). The large number of HBV
enhancer binding proteins and the presence of most of them
in both liver and nonliver cells suggests that the action of the
HBV enhancer may also involve complex interactions be-
tween specific and general transcription factors as well.
Accumulation of so many target sites in the enhancer might
have evolved to enable the enhancer to regulate transcrip-
tion of HBV genes at various stages of clinical expression of
viral infection. Similarly, such an enhancer would have
gained the flexibility to be transcriptionally active at all times
at various stages of liver differentiation as well. It remains to
be seen whether all or some of the factors involved in
binding to the HBV enhancer are required for eliciting
enhancer function during the various stages of liver differ-
entiation.
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ADDENDUM
Recently, we have been able to detect FP-VIII with HeLa
nuclear extracts as well. However, this protection is at least
1 order of magnitude weaker than that seen with RLNE.
ADDENDUM IN PROOF
NF-1 purified from HeLa cells binds to the enhancer at
three sites, including FP-I (1). However, with RLNE, an
NF-1 oligomer does not seem to compete with the FP-I,
suggesting that a factor(s) other than NF-1 might interact
with that sequence.
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